Royalty Pharma (RPRX) Net Cash Flow (2019 - 2026)
Royalty Pharma (RPRX) posted Net Cash Flow of -$32.3 million for Q1 2026, up 89.91% sequentially from -$320.2 million in Q4 2025, and down 120.35% YoY from $158.7 million in Q1 2025.
Royalty Pharma (RPRX) Net Cash Flow (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Net Cash Flow for 8 years, with the latest figure at -$32.3 million in Q1 2026.
- Quarterly Net Cash Flow fell 120.35% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$501.3 million (down 304.86% YoY) and the FY2025 annual result came in at -$310.3 million, down 168.65% from the prior year.
- Net Cash Flow rose to -$32.3 million in Q1 2026 per RPRX's latest filing, from -$320.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $921.6 million in Q2 2024 and troughed at -$1.2 billion in Q3 2023.
- A 5-year average of -$56.2 million and a median of $158.7 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 376.84% in 2022, then plunged 1423.1% in 2025.
- Over 5 years, Net Cash Flow stood at $719.1 million in 2022, then sank by 163.89% to -$459.4 million in 2023, then surged by 95.42% to -$21.0 million in 2024, then slumped by 1423.1% to -$320.2 million in 2025, then soared by 89.91% to -$32.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$32.3 million, -$320.2 million, and $307.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 225.59 Mn |
| Jun 30, 2026 | 225.59 Mn |
| Mar 31, 2026 | -32.30 Mn |
| Mar 31, 2026 | -32.30 Mn |
| Dec 31, 2025 | -320.25 Mn |
| Dec 31, 2025 | -320.25 Mn |
| Sep 30, 2025 | 307.04 Mn |
| Sep 30, 2025 | 307.04 Mn |
| Jun 30, 2025 | -455.81 Mn |
| Jun 30, 2025 | -455.81 Mn |
| Mar 31, 2025 | 158.69 Mn |
| Mar 31, 2025 | 158.69 Mn |
| Dec 31, 2024 | -21.03 Mn |
| Dec 31, 2024 | -21.03 Mn |
| Sep 30, 2024 | -814.59 Mn |
| Sep 30, 2024 | -814.59 Mn |
| Jun 30, 2024 | 921.64 Mn |
| Jun 30, 2024 | 921.64 Mn |
| Mar 31, 2024 | 365.99 Mn |
| Mar 31, 2024 | 365.99 Mn |